Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9680733 | 0.94 | PTGS2 (0.52) | CYP1A2ALOX5SMN1; SMN2CYP2D6TSHR | |
| SCHEMBL29318756 | 0.91 | CYP1A2 (0.48) | CYP1A2ALOX5SMN1; SMN2CYP2D6TSHR | |
| SCHEMBL421564 | 0.84 | PTGS2 (0.61) | CYP1A2ALOX5SMN1; SMN2TSHRPTGS2 | |
| SCHEMBL3860971 | 0.84 | PTGS2 (0.61) | CYP1A2ALOX5SMN1; SMN2TSHRPTGS2 | |
| SCHEMBL5149430 | 0.84 | PTGS2 (0.61) | CYP1A2ALOX5SMN1; SMN2TSHRPTGS2 | |
| SCHEMBL12280124 | 0.84 | CYP1A2 (0.55) | CYP1A2ALOX5SMN1; SMN2CYP2D6TSHR | |
| SCHEMBL4493827 | 0.82 | EPHX1 (0.58) | CYP1A2ALOX5SMN1; SMN2CYP2D6TSHR | |
| SCHEMBL2291864 | 0.82 | CYP1A2 (0.48) | CYP1A2ALOX5SMN1; SMN2CYP2D6TSHR | |
| SCHEMBL3875094 | 0.82 | EPHX1 (0.58) | CYP1A2ALOX5SMN1; SMN2CYP2D6TSHR | |
| SCHEMBL1290070 | 0.80 | CYP1A2 (0.47) | CYP1A2ALOX5SMN1; SMN2CYP2D6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109081830-A | Benzimidazole substituted diphenyl pyrimidine compound and organic electroluminescent device thereof | 昱镭光电科技股份有限公司 | 2018-12-25 | — | — | CN | disclosed |
| CN-107205391-A | Histone demethylase inhibitors | 赛尔基因昆蒂赛尔研究公司 | 2017-09-26 | — | — | CN | disclosed |
| CN-103304551-B | Hepatitis AG14361 | 北京凯因科技股份有限公司 | 2017-06-13 | — | — | CN | disclosed |
| EP-1487841-B1 | THIOPYRIMIDINE AND ISOTHIAZOLOPYRIMIDINE KINASE INHIBITORS | ABBVIE INC (US) | 2014-01-15 | — | — | EP | disclosed |
| CN-103304551-A | Hepatitis C polymerase inhibitor | BEIJING KAWIN TECHNOLOGY SHARE HOLDING CO LTD | 2013-09-18 | — | — | CN | disclosed |
| CN-103189353-A | Hydroxamate-based inhibitors of deacetylases | NOVARTIS AG | 2013-07-03 | — | — | CN | disclosed |
| CN-102026988-B | 3-substituted propanamines | SK HOLDINGS CO LTD | 2013-07-03 | — | — | CN | disclosed |
| CN-103189371-A | Novel hepatitis c virus inhibitors | THERAVANCE INC | 2013-07-03 | — | — | CN | disclosed |
| CN-101448802-B | Acrylamide derivative as histone deacetylase inhibitors for cancer treatment | DAC SRL | 2012-11-07 | — | — | CN | disclosed |
| CN-102026988-A | 3-substituted propanamines | SK HOLDINGS CO LTD | 2011-04-20 | — | — | CN | disclosed |
| US-20060276490-A1 | Thiopyrimidine and isothiazolopyrimidine Kinase Inhibitors | MICHAELIDES MICHAEL R | 2006-12-07 | — | — | US | disclosed |
| EP-1487841-A1 | THIOPYRIMIDINE AND ISOTHIAZOLOPYRIMIDINE KINASE INHIBITORS | Abbott Laboratories (US) | 2004-12-22 | — | — | EP | disclosed |
| US-20040014756-A1 | Thiopyrimidine and isothiazolopyrimidine kinase inhibitors | ABBVIE INC. | 2004-01-22 | — | — | US | disclosed |
| US-20030225273-A1 | Thiopyrimidine and isothiazolopyrimidine kinase inhibitors | ABBOTT LABORATORIES | 2003-12-04 | — | — | US | disclosed |
| WO-2003080625-A1 | THIOPYRIMIDINE AND ISOTHIAZOLOPYRIMIDINE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2003-10-02 | — | — | WO | disclosed |
| US-20030181468-A1 | Thiopyrimidine and isothiazolopyrimidine kinase inhibitors | ABBOTT LABORATORIES | 2003-09-25 | — | — | US | disclosed |
| CN-1329648-A | Material consisting of cyanoacrylate and aldehyde-or ketone-condensation products for adhesives, coatings and sealants | HENKEL KGAA (DE) | 2002-01-02 | — | — | CN | disclosed |
| CN-1252070-A | 5,7-disubstituted 4-aminopyrido [2,3,-d] pyrimidine compounds and their use as adenosine kinase inhibitors | ABBOTT LAB (US) | 2000-05-03 | — | — | CN | disclosed |
| US-5136013-A | Polyesters | BAYER AKTIENGESELLSCHAFT (DE) | 1992-08-04 | — | — | US | disclosed |
| US-5068300-A | BIFUNCTIONAL STILBENE COMPOUNDS CONTAINING AT LEAST ONE Z-CONFIGURATED STILBENE GROUP, PROCESS FOR THEIR PREPARATION AND THEIR USE FOR THE PREPARATION OF POLYMERS | BAYER AKTIENGESELLSCHAFT (DE) | 1991-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014756-A1 | Thiopyrimidine and isothiazolopyrimidine kinase inhibitors | ABL1, ERBB2, LCK | CYP1A2 2572/4885ALOX5 4023/4885SMN1; SMN2 4282/4885 |
| US-20060276490-A1 | Thiopyrimidine and isothiazolopyrimidine Kinase Inhibitors | ABL1, LCK, ERBB2 | CYP1A2 3262/4885ALOX5 3771/4885SMN1; SMN2 4409/4885 |
| US-20030225273-A1 | Thiopyrimidine and isothiazolopyrimidine kinase inhibitors | ABL1, ERBB2, LCK | CYP1A2 2572/4885ALOX5 4023/4885SMN1; SMN2 4282/4885 |
| US-20030181468-A1 | Thiopyrimidine and isothiazolopyrimidine kinase inhibitors | ABL1, ERBB2, LCK | CYP1A2 2586/4885ALOX5 3949/4885SMN1; SMN2 4369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.